Healthspan-focused biotech LinkGevity revealed has been selected for the prestigious KQ Labs Programme, delivered by the Francis Crick Institute. The program provides equity investment and access to a global network of scientific expertise, selecting 10 startups annually through a rigorous evaluation process.

Founded by sisters Dr Carina Kern and Serena Kern-Libera, LinkGevity is an AI-driven drug discovery company focused on addressing age-related diseases and extending healthspan. The company’s mission is rooted in the belief that aging can be addressed at its biological source.

The company’s approach is built on Kern’s own Blueprint Theory of Aging, which identifies molecular pathways that drive aging and age-related diseases. According to the theory, these pathways are the molecular source of “destructive cascades underlying multiple age-related conditions.”

Click below to read the full article or pop on to LinkGevity's website to find out more.